Safety and efficacy of exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy: 52-week results of the DURATION-8 randomized controlled trial
As weve explored, it is classified as water soluble, which has significant implications for its bioavailability and functionality within the body
To assess whether the imbalance in age and sex between cases and controls could introduce residual confounding or collider bias, we performed an age and sex matched sensitivity analysis
Oxidative stress, molecular inflammation and sarcopenia
Phase 1b/2a Subcutaneous Formulation (Obesity) Published: The Lancet, June 2025 Participants: 125 adults with overweight or obesity (BMI 27.039.9), aged 1855 Duration: Up to 36 weeks Dosing: Once-weekly subcutaneous amycretin, up to 60 mg Results: - Up to 22% absolute weight loss at 36 weeks (highest dose group) - Placebo-adjusted difference: approximately 24% - No weight-loss plateau observed at study end Safety: 81% of the 89 participants who reported a TEAE had gastrointestinal events
Frequently Asked Questions About Vitamin B12 Injections Who can benefit from Vitamin B12 injections
